Ionis Pharmaceuticals (IONS) Price & Analysis

Compare

1,364 Followers

IONS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$23.95 - $52.34

Previous CloseN/A

Volume126.35K

Average Volume (3M)1.80M

Market Cap

$6.64B

Enterprise Value$7.83B

Total Cash (Recent Filing)$2.15B

Total Debt (Recent Filing)$1.41B

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Jul 31, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.93

Shares Outstanding159,159,100

10 Day Avg. Volume1,965,078

30 Day Avg. Volume1,798,833

Financial Highlights & Ratios

PEG Ratio-8.80

Price to Book (P/B)13.93

Price to Sales (P/S)0.00

P/FCF Ratio-11.67

Enterprise Value/Market Cap1.18

Enterprise Value/Revenue2.58

Enterprise Value/Gross Profit11.17

Enterprise Value/Ebitda-6.34

Forecast

1Y Price Target

$58.33

Price Target Upside39.78% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering18

Ionis Pharmaceuticals News

See All News >

Bulls Say, Bears Say

Bulls Say

Clinical TrialsMomentum is building ahead of Phase 3 CORE/CORE-2 data for olezarsen in severe hypertriglyceridemia, with favorable risk/reward expectations.

Drug DevelopmentFavorable Phase 1 salanersen spinal muscular atrophy data proves sufficient to advance the drug into pivotal trials.

Market OpportunityAnalysts expect positive results from Phase 3 CORE/CORE2 studies, potentially expanding the market opportunity for Tryngolza.

Bears Say

Data AvailabilityFavorable trends on acute pancreatitis event rates will be needed to drive meaningful upside, but data may not be available until a later date.

Patient CharacteristicsThe readthrough to pivotal CORE/CORE2 studies is limited due to differences in patient characteristics compared to the ESSENCE study.

Financials

Income Statement >

Options Prices

Detailed Option Prices >

Ownership Overview

0.80% Insiders

43.47% Mutual Funds

0.10% Other Institutional Investors

40.53% Public Companies and Individual Investors

Detailed Ownership Overview >

IONS FAQ

What was Ionis Pharmaceuticals Inc.’s price range in the past 12 months?

Ionis Pharmaceuticals Inc. lowest stock price was $23.95 and its highest was $52.34 in the past 12 months.

What is Ionis Pharmaceuticals Inc.’s market cap?

Ionis Pharmaceuticals Inc.’s market cap is $6.64B.

When is Ionis Pharmaceuticals Inc.’s upcoming earnings report date?

Ionis Pharmaceuticals Inc.’s upcoming earnings report date is Jul 31, 2025 which is in 15 days.

How were Ionis Pharmaceuticals Inc.’s earnings last quarter?

Ionis Pharmaceuticals Inc. released its earnings results on Apr 30, 2025. The company reported -$0.93 earnings per share for the quarter, beating the consensus estimate of -$1.098 by $0.168.

Is Ionis Pharmaceuticals Inc. overvalued?

According to Wall Street analysts Ionis Pharmaceuticals Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ionis Pharmaceuticals Inc. pay dividends?

Ionis Pharmaceuticals Inc. does not currently pay dividends.

What is Ionis Pharmaceuticals Inc.’s EPS estimate?

Ionis Pharmaceuticals Inc.’s EPS estimate is -0.24.

How many shares outstanding does Ionis Pharmaceuticals Inc. have?

Ionis Pharmaceuticals Inc. has 159,159,100 shares outstanding.

What happened to Ionis Pharmaceuticals Inc.’s price movement after its last earnings report?

Ionis Pharmaceuticals Inc. reported an EPS of -$0.93 in its last earnings report, beating expectations of -$1.098. Following the earnings report the stock price went up 3.019%.

Which hedge fund is a major shareholder of Ionis Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in IONS

Ionis Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-118.53%

Trailing 12-Months

Asset Growth

1.77%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals (IONS) is a biotechnology company headquartered in Carlsbad, California. It specializes in discovering and developing RNA-targeted therapeutics, primarily focusing on antisense oligonucleotide technology. Ionis is recognized for its innovative approach to treating a wide range of diseases, including neurological disorders, cardiovascular diseases, and cancer. The company develops drugs both independently and through strategic collaborations with leading pharmaceutical companies.

IONS Company Deck

IONS Earnings Call

Q1 2025

0:00 / 0:00

IONS Stock 12 Month Forecast

Average Price Target

$58.33

▲(39.78%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","79":"$79","39.25":"$39.3","52.5":"$52.5","65.75":"$65.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$78.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,39.25,52.5,65.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,37.48615384615385,40.862307692307695,44.238461538461536,47.614615384615384,50.99076923076923,54.36692307692307,57.74307692307692,61.11923076923077,64.49538461538461,67.87153846153846,71.2476923076923,74.62384615384616,{"y":78,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,35.973076923076924,37.83615384615385,39.699230769230766,41.56230769230769,43.425384615384615,45.28846153846154,47.151538461538465,49.01461538461538,50.87769230769231,52.74076923076923,54.60384615384615,56.46692307692308,{"y":58.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,34.11,34.40923076923077,34.708461538461535,35.00769230769231,35.30692307692308,35.606153846153845,35.90538461538461,36.20461538461539,36.503846153846155,36.80307692307692,37.10230769230769,37.401538461538465,37.70076923076923,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.57,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >